Procurement Of Drugs Purchase Of Drugs (Oncology, Growth Factor, Antiemetic) , 1.01 To 1.02- 5-Fluorouracile - (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , 5-Fluorouracil , 5-Fluorouracil , 2.01 To 2.02- 5-Fluorouracil (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , 5-Fluorouracil , 5-Fluorouracil , 3.01 To 3.02- Abemaciclib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Abemaciclib , Abemaciclib , 4.01 To 4.02- Bosutinib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Bosutinib , Bosutinib , 5.01 To 5.03- Cabozantinib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Cabozantinib , Cabozantinib , Cabozantinib , 6.01 To 6.03- Carfilzomib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Carfilzomib , Carfilzomib , Carfilzomib , 7.01 To 7.02- Chlorambucil (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Chlorambucil , Chlorambucil , 8.01 To 8.03- Cyclophosphamide Powder (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Cyclophosphamide Powder , Cyclophosphamide Powder , Cyclophosphamide Powder , 9.01 To 9.03- Cyclophosphamide Rtd (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Cyclophosphamide Rtd , Cyclophosphamide Rtd , Cyclophosphamide Rtd , 10.1 To 10.3- Dacarbazine (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Dacarbazine , Dacarbazine , Dacarbazine , 11.01 To 11.02- Dacomitinib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Dacomitinib , Dacomitinib , 12.01 To 12.06- Darbepoetin (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Darbepoetin , Darbepoetin , Darbepoetin , Darbepoetin , Darbepoetin , Darbepoetin , 13.01 To 13.02- Decitabine (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Decitabine , Decitabine , 14.01 To 14.02- Durvalumab (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Durvalumab , Durvalumab , 15.01 To 15.04- Everolimus (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Everolimus , Everolimus , Everolimus , Everolimus , 16.01 To 16.02- Everolimus (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Everolimus , Everolimus , 17.01 To 17.02- L-Asparaginase (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , L-Asparaginase , L-Asparaginase , 18.01 To 18.02- Lorlatinib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Lorlatinib , Lorlatinib , 19.01 To 19.02 -Luspatercept (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Luspatercept , Luspatercept , 20.01 To 20.02 -Megestrol (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Megestrol , Megestrol , 21.01 To 21.03 - Mitomycin-C (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Mitomycin-C , Mitomycin-C , Mitomycin-C , 22.01 To 22.02- Nanosomal Paclitaxel Lipid Suspension (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Nanosomal Paclitaxel Lipid Suspension (Npls) For Inj , Nanosomal Paclitaxel Lipid Suspension (Npls) For Inj , 23.01 To 23.02 - Nilotinib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Nilotinib , Nilotinib , 24.01 To 24.02 -Nintedanib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Nintedanib , Nintedanib , 25.01 To 25.02- Octreotide (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Octreotide , Octreotide , 26.01 To 26.03- Octreotide Lar (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Octreotide Lar , Octreotide Lar , Octreotide Lar , 27.01 To 27.02 -Olaparib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Olaparib , Olaparib , 28.01 To 28.02- Osimertinib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Osimertinib , Osimertinib , 29.01 To 29.03- Pegylated Interferon Alfa 2B (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Pegylated Interferon Alfa 2B , Pegylated Interferon Alfa 2B , Pegylated Interferon Alfa 2B , 30.01 To 30.02- Pertuzumab+Trastuzumab (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Pertuzumab+Trastuzumab , Pertuzumab+Trastuzumab , 31.01 To 31.02- Polatuzumab Vedotin (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Polatuzumab Vedotin , Polatuzumab Vedotin , 32.01 To 32.03 - Pomalidomide (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Pomalidomide , Pomalidomide , Pomalidomide , 33.01 To 33.02 - Ramucirumab (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Ramucirumab , Ramucirumab , 34.01 To 34.02- Recombinant Human Interferon Alfa 2B(Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Recombinant Human Interferon Alfa 2B , Recombinant Human Interferon Alfa 2B , 35.01 To 35.02- Rucaparib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Rucaparib , Rucaparib , 36.01 To 36.03- Ruxolitinib (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Ruxolitinib , Ruxolitinib , Ruxolitinib , 37.01 To 37.02 -Teclistamab (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Teclistamab , Teclistamab , 38.01 To 38.02 -S1 Therapy Tegfur+Gimeracil+Oteracil (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , S1 Therapy Tegfur+Gimeracil+Oteracil , S1 Therapy Tegfur+Gimeracil+Oteracil , 39.01 To 39.02- Thalidomide (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Thalidomide , Thalidomide , 40.01 To 40.03- Tocilizumab (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Tocilizumab , Tocilizumab , Tocilizumab , 41.01 To 41.03- Venetoclax (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Venetoclax , Venetoclax , Venetoclax , 42.01 To 42.02- Vinorelbine (Quoting For All Strength Is Preferable, Technically Shortlisted Innovators/Originals , L1 & L2 Will Be Selected Based On Consolidated Results) , Vinorelbine , Vinorelbine , Name Of The Items , Acalabrutinib , Alectinib , All Trans Retinoic Acid(Tretinoin) , Alpelisib , Alpelisib , Alteplase , Amivantamab , Amphotericin B Liposomal In Ns , Anastrozole , Apalutamide , Arsenic Trioxide , Asciminib , Atezolizumab , Avelumab , Bicalutamide , Bleomycin , Bortezomib , Brentuximab Vedotin , Busulphan , Busulphan , Cabazitaxel , Capecitabine+Cyclophosphamide , Capecitabine+Cyclophosphamide , Capmatinib , Carmustine , Ceritinib , Cetuximab , Cladribine , Clofarabine , Cyclophosphamide , Dabrafenib , Dabrafenib , Dactinomycin , Daratumumab+Hyaluronidase Fihj Subcutaneous , Darolutamide , Daunorubicin , Docetaxel Nanosomal(Lipid Suspension) , Docetaxel Nanosomal(Lipid Suspension) , Docetaxel Nanosomal(Lipid Suspension) , Entrectinib , Entrectinib , Enfortumab Vedotin , Enfortumab Vedotin , Enzalutamide Syrup 150 Ml , Eribulin , Erythropoietin , Erythropoietin , Erythropoietin , Erythropoietin , Erythropoietin , Erythropoietin , Erythropoietin , Erythropoietin , Estramustine , Etoposide , Factor Vii Eptacog Alfa(Human Recombinant Coagulation Factor Vii Activated R-Dna Origin) , Factor Vii Eptacog Alfa(Human Recombinant Coagulation Factor Vii Activated R-Dna Origin) , Fludarabine , Fludarabine , Flunarizine , Flutamide , Fosaprepitant Dimeglumine , Fosfestrol , Fosnetupitant+Palonosetron , Gliteritinib , Granisetron , Granisetron , Granisetron Md , Goserelin , Goserelin , Hydroxyurea , Hydroxyurea , Ibandronic Acid , Ibandronic Acid , Ibandronic Acid , Ibrutinib , Idarubicin , Infleximab , Inotuzumab Ozogamicin , Interferon Alpha 2B , Ipilimumab , Irinotecan Liposomal , Isavuconazole , Isavuconazole , Leucovorin Calcium , Leucovorin Calcium , Leucovorin Calcium , Leuprolide Acetate , Lomustine , Melphalan , Melphalan , Melphalan , Mercaptopurine , Mercaptopurine 100 Ml , Mesna (3*2 Ml Pack) Inj , Mesna 1*2 Ml Inj , Mesna Respiratory Solution , Methotrexate , Methotrexate , Methotrexate , Methotrexate , Methotrexate , Methotrexate , Midostaurin , Mitoxantrone , Mycobacterium W.(Heat Killed) Immunomodulator Inj , Nelarabine , Nimotuzumab , Obinutuzumab , Ondansetron , Ondansetron , Ondansetron , Ondansetron , Ondansetron 30 Ml Syrup , Ondansetron Md , Ondansetron Md , Ondansetron Ods , Ondansetron Ods , Paclitaxel Albumin Bound Nano Particle , Palanosetron , Palanosetron , Palanosetron , Palanosetron+Netupitant , Palanosetron+Netupitant , Panitumumab , Pegaspargase , Pembrolizumab , Pertuzumab , Plerixafor , Procarbazine , Rasburicase , Regorafenib , Relugolix , Ribociclib , Romiplostim , Sargramostim , Sirolimus , Sorafenib , Tamoxifen , Tamoxifen , Tegfur+Uracil , Tepotinib , Thioguanine , Thiotepa , Thiotepa , Thyrotropin Alfa , Topotecan , Toripalimab , Trabectedin , Trametinib , Trastuzumab Deruxtecan , Trifluridine+Tipiracil , Trifluridine+Tipiracil , Triptorelin , Triptorelin , Triptorelin Pamoate , Tremelimumab , Tucatinib , Tucatinib , Valganciclovir , Vinblastin , Vincristine , Vincristine , Voriconazole , Zoledronic Acid , Zoledronic Acid
